

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK
VARIABLE LIFE INSURANCE
COMPANY and MANULIFE
INSURANCE COMPANY,

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendant.

CIVIL ACTION NO. 05-11150-DPW

**ERRATA RE: ABBOTT'S CORRECTED DEPOSITION COUNTER-
DESIGNATIONS FOR STANLEY BUKOFZER**

Defendant Abbott Laboratories ("Abbott") respectfully submits this Errata in connection with Abbott's Corrected Deposition Counter-Designations for the May 17, 2007 deposition of Stanley Bukofzer, MBBCh., M.Med., former Head of the Anti-Infective Venture (ABT-773). Abbott inadvertently filed the incorrect designation chart and incorrect highlighted page of the deposition excerpt for the Stanley Bukofzer deposition. A true and correct copy of the correct chart and corrected highlighted deposition excerpt page are attached hereto. Abbott will be submitting corrected courtesy copies of the Stanley Bukofzer deposition counter-designations to the Court.

Dated: February 26, 2008

Respectfully submitted,

ABBOTT LABORATORIES

By: /s/ Eric J. Lorenzini
Eric J. Lorenzini

Jeffrey I. Weinberger (*pro hac vice*)
Gregory D. Phillips (*pro hac vice*)
Eric J. Lorenzini (*pro hac vice*)
Ozge Guzelsu (*pro hac vice*)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, Thirty-Fifth
Floor
Los Angeles, CA 90071-1560
Tele: (213) 683-9100

and

Peter E. Gelhaar (BBO#188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY &
GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880
peg@dcglaw.com
msd@dcglaw.com

Counsel for Abbott Laboratories

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 26, 2008.

Date: February 26, 2008

/s/ Ozge Guzelsu

Stanley Bukofzer Deposition Designations

Date	Witness	Hancock Desig	Abbott Counter Desig	Abbott Desig	Hancock Counter Desig	Deposition Exhibit	Plaintiff Exhibit	Defendant Exhibit
5/9/07	Bukofzer, Stanley	15:24- 16:6						
5/9/07	Bukofzer, Stanley	56:2- 56:22						
5/9/07	Bukofzer, Stanley	57:2- 57:15						
5/9/07	Bukofzer, Stanley		57:16- 57:17					
5/9/07	Bukofzer, Stanley	72:10- 72:18						
5/9/07	Bukofzer, Stanley		72:19- 73:13					
5/9/07	Bukofzer, Stanley	73:14- 73:23						
5/9/07	Bukofzer, Stanley		73:24- 74:6					
5/9/07	Bukofzer, Stanley	78:6- 78:13						
5/9/07	Bukofzer, Stanley		78:14- 79:6					
5/9/07	Bukofzer, Stanley		79:17- 80:23					
5/9/07	Bukofzer, Stanley	93:24- 94:7						
5/9/07	Bukofzer, Stanley		94:8-95:8					
5/9/07	Bukofzer, Stanley	95:9-96:8						
5/9/07	Bukofzer, Stanley	108:21- 109:8						
5/9/07	Bukofzer, Stanley	147:3- 147:7						
5/9/07	Bukofzer, Stanley	149:17- 149:20						
5/9/07	Bukofzer, Stanley	166:15- 166:21				9	IM	
5/9/07	Bukofzer, Stanley		166:23- 167:4					
5/9/07	Bukofzer, Stanley		168:3- 168:12					
5/9/07	Bukofzer, Stanley	168:19- 169:6				9	IM	
5/9/07	Bukofzer, Stanley		169:7- 169:17					
5/9/07	Bukofzer, Stanley	171:16- 173:24				9	IM	
5/9/07	Bukofzer, Stanley		174:1- 174:17					
5/9/07	Bukofzer, Stanley		175:7- 175:13					
5/9/07	Bukofzer, Stanley	175:15- 175:18						

5/9/07	Bukofzer, Stanley		176:4- 176:8					
5/9/07	Bukofzer, Stanley	223:1- 223:10				13	JA	
5/9/07	Bukofzer, Stanley	226:19- 227:6	325:16- 328:7			13	JA	
5/9/07	Bukofzer, Stanley		227:7- 228:2					
5/9/07	Bukofzer, Stanley	295:10- 295:17				23	QM	
5/9/07	Bukofzer, Stanley	298:16- 299:10				23	QM	
5/9/07	Bukofzer, Stanley		299:20- 299:23					
5/9/07	Bukofzer, Stanley	300:14- 300:19				23	QM	
5/9/07	Bukofzer, Stanley		300:20- 301:1					
5/9/07	Bukofzer, Stanley	301:2- 301:12				23	QM	
5/9/07	Bukofzer, Stanley		301:13- 301:17					
5/9/07	Bukofzer, Stanley	301:18- 301:24						

1 A. Correct.

2 Q. You said there was a preference for

3 once-a-day dosing. Was that across all

4 indications for 773 or just some?

5 A. As I recall, it was -- if I can just

6 step back and just expand on that, it was a

7 preference for the U.S. commercial team to have

8 once-daily dosing. The issue was not seen as

9 imp- -- as that important in the rest of the

10 world. In fact, in some parts of the world, such

11 as Japan, it was seen as preferable to have a more

12 frequent dosing.

13 So coming back to your specific

14 question for "all indications," I think that the

15 preference was there for all indications. But,

16 again, there was a rank order of which ones were

17 more important and which were less important.

18 Q. Dr. Bukofzer, when you became head of

19 the venture in April of 2001, was it your

20 understanding that the dosing decision was the

21 most important decision facing the successful

22 development of 773?

23 A. I don't think that that's characterized

24 correctly. I think it was one of the very